Anbio Biotechnology (NNNN) filed a shelf registration statement on Thursday for the potential sale of securities from time to time.
The filing includes Class A ordinary shares, share purchase contracts, share purchase units, warrants, debt securities, rights and units.
Net proceeds will be used to fund research, clinical development and product commercialization, as well as for general corporate purposes.
Anbio shares fell 5.9% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments